Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Added: 2 months ago Source:  Radcliffe Cardiology
For patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), the net effect of right ventricular pacing (RVP) has been variable, as it can reduce the left ventricular outflow tract gradient (LVOTg) but may also decrease cardiac output.¹ The EMORI-HCM trial investigated whether electromechanically optimising the atrio-ventricular delay (AVD) could allow RVP to achieve a consistent… View more
Added: 3 months ago Source:  Radcliffe Cardiology
An exploratory analysis of the ODYSSEY-HCM trial has shown that mavacamten significantly reduces key cardiac biomarkers in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), a condition with no approved therapies.¹ While the main trial did not meet its primary endpoints of improving functional capacity or patient-reported health status, these biomarker findings suggest a… View more
Added: 4 months ago Source:  Radcliffe Cardiology
New findings from a large, international registry suggest that in patients with the dual pathology of aortic stenosis and transthyretin-associated cardiac amyloidosis, a combination of aortic valve replacement and disease-specific medication offers the most significant survival benefit.¹ The study (NCT06129331) aimed to clarify the prognostic impact of these treatments in this increasingly… View more
Added: 6 months ago Source:  Radcliffe Cardiology
AUTHOR: Jordan RanceRisk stratification for primary prevention implantable cardioverter-defibrillator (ICD) placement in patients with cardiac sarcoidosis remains a clinical challenge, partly due to inconsistencies in diagnostic criteria and the variable course of the disease. A new study published in the European Heart Journal suggests that cardiovascular magnetic resonance (CMR) phenotyping has… View more
Added: 5 months ago Source:  Radcliffe Cardiology
A prespecified secondary analysis of the DAN-RSV trial has found that a bivalent respiratory syncytial virus (RSV) vaccine is similarly effective against respiratory and cardiovascular outcomes in older adults, regardless of pre-existing atherosclerotic cardiovascular disease (ASCVD).¹The bivalent RSV prefusion F protein-based (RSVpreF) vaccine contains stabilised prefusion F glycoproteins from… View more
Added: 7 months ago Source:  Radcliffe Cardiology
New research challenges the common assumption that high flow rates during venoarterial extracorporeal membrane oxygenation (VA-ECMO) increase pulmonary capillary wedge pressure (PCWP) and the risk of pulmonary oedema in patients with cardiogenic shock. The ECMO-Flow trial found that increasing VA-ECMO flow often has a neutral or even beneficial effect on PCWP, despite raising left ventricular… View more
Added: 8 months ago Source:  Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal disease characterised by the deposition of amyloid fibrils in the heart. A new analysis from the HELIOS-B trial has found that key echocardiographic measures are strong predictors of clinical outcomes and that the RNA interference (RNAi) therapeutic vutrisiran attenuates the decline in cardiac function in this patient… View more
Added: 5 months ago Source:  Radcliffe Cardiology
New long-term data from the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial suggests that sustained, intensive blood pressure (BP) control provides greater cardiovascular benefits compared to a delayed approach in older patients with hypertension.¹ The findings also indicate that the earlier intensive treatment is initiated, the greater the reduction in… View more
Added: 3 months ago Source:  Radcliffe Cardiology
Intensive blood pressure (BP) control is beneficial for high-risk hypertensive patients, regardless of their frailty status, according to a new post hoc analysis of the ESPRIT trial.¹ The findings suggest that even severely frail patients can safely achieve cardiovascular benefits from a lower systolic BP target.MethodologyThis analysis was conducted on data from the ESPRIT (Effects of intensive… View more
Added: 8 months ago Source:  Radcliffe Cardiology
A new meta-analysis suggests that the more time an individual's ambulatory blood pressure (ABP) is within the target range proposed by the 2024 European Society of Cardiology (ESC) guidelines, the lower their risk of mortality and cardiovascular events.¹ The findings also highlight that office blood pressure measurements frequently misclassify patients with regard to their actual blood pressure… View more